Duligotuzumab

N/A

Report date: 2023/04/23 20:00:31

Base Information

Drug NameDuligotuzumab

Drug Alias NameAnti-HER3/EGFR DAFDuligotuzmab (Duligotumab)Duligotuzumab (Genentech)RO-5541078RG-7597 +[6]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsReceptor tyrosine-protein kinase erbB-3 antagonists

TargetsEpidermal growth factor receptor erbB1Receptor tyrosine-protein kinase erbB-3

Therapy Area/IndicationsHead and Neck NeoplasmsColorectal NeoplasmsCarcinoma +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumBulgariaUnited States +[12]

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGenentech Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGenentech Inc

Active IndicationsN/A

Inactive IndicationsHead and Neck NeoplasmsColorectal NeoplasmsCarcinoma +[4]

Other Information

ATC CodeN/A